DDInter833 DDInter629
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634]
Glycerol phenylbutyrate {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Phenylbutazone
Phenylbutazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Dextropropoxyphene
Dextropropoxyphene {u} may lead to a major life threatening interaction when taken with {v} Eliglustat
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Glycerol phenylbutyrate {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Bepridil
Bepridil {u} may lead to a major life threatening interaction when taken with {v} Eliglustat
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Trazodone
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Glycerol phenylbutyrate {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Dextropropoxyphene
Dextropropoxyphene {u} may lead to a major life threatening interaction when taken with {v} Eliglustat
Glycerol phenylbutyrate (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Glycerol phenylbutyrate (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Dextropropoxyphene (Compound) and Dextropropoxyphene may lead to a major life threatening interaction when taken with Eliglustat
Glycerol phenylbutyrate (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Glycerol phenylbutyrate (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Bepridil (Compound) and Bepridil may lead to a major life threatening interaction when taken with Eliglustat
Glycerol phenylbutyrate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Trazodone (Compound) and Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Glycerol phenylbutyrate (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Dextropropoxyphene (Compound) and Dextropropoxyphene may lead to a major life threatening interaction when taken with Eliglustat